Michael Platten has shown that IDH1R132H is an immunogenic tumor antigen that induces mutation-specific CD4+ T cell and antibody responses that are capable of controlling IDH1R132H-expressing tumor growth in vivo in MHC-humanized A2.DR1 mice after vaccination; because of its CD4+ T cell-dependent manner, IDH1R132H is suitable for adoptive cell therapy (75). This evidence concerns the gene CD4 and neoplasm.